Danish pharma big Novo Nordisk teased promising early-phase demo final results of its experimental weight loss capsule amycretin, sending the corporate’s stock surging.GLP-1 agonist medications, normally known as GLP-1s, are injectable drugs that operate by mimicking the GLP-1 hormone that your little intestine will make in response to food stuff